Table 3.
Variable | MMR-deficient tumors | MMR-proficient tumors | ||||
---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |||
CD3+ at invasive margin (low vs high) | 4.76 (1.43–15.87) | 0.0019 | 3.39 (1.16–9.90) | 0.0103 | ||
T stage | T3 vs T1–2 T4 vs T1–2 |
—b | 0.0086 | 1.29 (0.38–4.37) 2.72 (0.73–10.13) |
0.0994 | |
N stage | N2 vs N1 | 4.52 (2.49–8.19) | <.0001 | 3.68 (1.98–6.84) | <.0001 | |
Histologic grade (high vs low) | 0.77 (0.42–1.43) | 0.3751 | 1.64 (0.90–2.98) | 0.1130 | ||
Tumor side (left vs right) | 1.13 (0.51–2.51) | 0.7658 | 0.70 (0.36–1.37) | 0.2980 | ||
Mutation status |
KRAS-mutated vs both wild-type BRAF-mutated vs both wild-type |
0.77 (0.28–2.14) 1.17 (0.58–2.36) |
0.7305 | 1.75 (0.93–3.29) 2.68 (1.03–6.98) |
0.0828 | |
Smoking (ever vs never) | 0.77 (0.42–1.43) | 0.4031 | 0.88 (0.49–1.57) | 0.6620 | ||
Age (per 5-year increase) | 1.12 (0.98–1.28) | 0.0980 | 1.25 (1.09–1.43) | 0.0010 |
CD3+ at invasive margin was dichotomized at an optimized cutpoint value. HRs are adjusted for all variables shown
Precise HR could not be estimated since there were no events in the T1–2 subgroup.
Abbreviations: HR, hazard ratio; MMR, mismatch repair